CompletedPHASE2, PHASE3NCT02231879
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Studying Acquired neutropenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- David H McDermott, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Plerixafor(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 10-75 years · All sexes
- Timeline
- 2014 – 2021
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02231879 on ClinicalTrials.govOther trials for Acquired neutropenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06056297A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsX4 Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT00967785A Phase I Study of Mozobil in the Treatment of Patients With WHIMSNational Institute of Allergy and Infectious Diseases (NIAID)